Non-Canonical Smads Phosphorylation Induced by the Glutamate Release Inhibitor, Riluzole, through GSK3 Activation in Melanoma
Open Access
- 12 October 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10) , e47312
Abstract
Riluzole, an inhibitor of glutamate release, has shown the ability to inhibit melanoma cell xenograft growth. A phase 0 clinical trial of riluzole as a single agent in patients with melanoma resulted in involution of tumors associated with inhibition of both the mitogen-activated protein kinase (MAPK) and phophoinositide-3-kinase/AKT (PI3K/AKT) pathways in 34% of patients. In the present study, we demonstrate that riluzole inhibits AKT-mediated glycogen synthase kinase 3 (GSK3) phosphorylation in melanoma cell lines. Because we have demonstrated that GSK3 is involved in the phosphorylation of two downstream effectors of transforming growth factor beta (TGFβ), Smad2 and Smad3, at their linker domain, our aim was to determine whether riluzole could induce GSK3β-mediated linker phosphorylation of Smad2 and Smad3. We present evidence that riluzole increases Smad2 and Smad3 linker phosphorylation at the cluster of serines 245/250/255 and serine 204 respectively. Using GSK3 inhibitors and siRNA knock-down, we demonstrate that the mechanism of riluzole-induced Smad phosphorylation involved GSK3β. In addition, GSK3β could phosphorylate the same linker sites in vitro. The riluzole-induced Smad linker phosphorylation is mechanistically different from the Smad linker phosphorylation induced by TGFβ. We also demonstrate that riluzole-induced Smad linker phosphorylation is independent of the expression of the metabotropic glutamate receptor 1 (GRM1), which is one of the glutamate receptors whose involvement in human melanoma has been documented. We further show that riluzole upregulates the expression of INHBB and PLAU, two genes associated with the TGFβ signaling pathway. The non-canonical increase in Smad linker phosphorylation induced by riluzole could contribute to the modulation of the pro-oncogenic functions of Smads in late stage melanomas.Keywords
This publication has 61 references indexed in Scilit:
- The Urokinase Plasminogen Activator System: A Target for Anti-Cancer TherapyCurrent Cancer Drug Targets, 2009
- Smad3 phosphorylation by cyclin-dependent kinasesCytokine & Growth Factor Reviews, 2006
- Identification and Characterization of ERK MAP Kinase Phosphorylation Sites in Smad3Biochemistry, 2005
- Role of Rho/ROCK and p38 MAP Kinase Pathways in Transforming Growth Factor-β-mediated Smad-dependent Growth Inhibition of Human Breast Carcinoma Cells in VivoJournal of Biological Chemistry, 2005
- Overexpression of activin A in stage IV colorectal cancerGut, 2001
- Mechanisms of action of flavopiridolCritical Reviews in Oncology/Hematology, 2001
- Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.2000
- Molecular classification of cutaneous malignant melanoma by gene expression profilingNature, 2000
- A mechanism of repression of TGFbeta / Smad signaling by oncogenic RasGenes & Development, 1999
- Phosphorylation of Ser465 and Ser467 in the C Terminus of Smad2 Mediates Interaction with Smad4 and Is Required for Transforming Growth Factor-β SignalingJournal of Biological Chemistry, 1997